CompletedInterventionalPhase 2Updated Feb 14, 2012
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension | NCT00287521 | Trialant
CompletedInterventionalPhase 2Updated Mar 5, 2012
A Study of Glaucoma Therapy to Treat Open-Angle Glaucoma or Ocular Hypertension
ClinicalTrials.gov ID
NCT00287521
Lead Sponsor
Alcon ResearchINDUSTRY
Overall Status
Completed
Study Type
Interventional
Phase
Phase 2
Enrollment
87Actual
Last Update Posted
Mar 5, 2012Estimated
Start Date
Nov 2005
Primary Completion Date
Feb 2006Actual
Completion Date
Feb 2006Actual
Brief Summary
The purpose of this study is to determine whether a glaucoma therapy is safe and effective in treating patients with open-angle glaucoma or ocular hypertension.
Open-angle Glaucoma
Ocular Hypertension
AL-37807 Ophthalmic Suspension, 1.0%
Latanoprost, 0.005% (Xalatan)
AL-37807 Vehicle
Timolol Maleate Ophthalmic Gel Forming Solution, 0.5%
Ages Eligible for Study
Adult (18-64)Older Adult (65+)
Sexes Eligible for Study
All
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Diagnosed with open-angle glaucoma (with ot without pseudoexfoliation or pigment dispersion component) or ocular hypertension
Other protocol-defined inclusion criteria may apply.
Exclusion Criteria:
Under 18
Other protocol-defined exclusion criteria may apply.
Primary Purpose
Treatment
Allocation
Randomized
Interventional Model
Parallel Assignment
Masking
Double
No central contacts
There are no central contacts for this study.
United States Investigative Sites in Texas and Other States